Vascular endothelial growth factor (VEGF) as marker of pulmonary hypertension in children with asthma

The development of pulmonary hypertension in patients with bronchial asthma is almost always associated with structural changes of the vascular bed - pulmonary vascular remodeling. VEGF is one of the most informative factors, reflecting the initial changes in the microvasculature. In this regard, the definition of VEGF in serum of patients may help identify the preconditions for the formation of pulmonary hypertension in children with asthma. Aim: To evaluate the role of vascular endothelial growth factor in the genesis of pulmonary hypertension in children with asthma. Methods: 30 patients with asthma were examined during the period of exacerbation. All patients underwent a comprehensive study of the cardiovascular system with the use of echocardiography. VEGF concentration in serum was determined by enzyme immunoassay. Results: The increase of improving blood flow rate and the pulmonary artery pressure is set at 20% children with asthma. The concentration of VEGF in patients with high blood flow to the pulmonary artery (81,48 ± 12,41 pg / mmol) considerably exceeds the average children without echocardiographic evidence of pulmonary hypertension (55,71 ± 19,40 pg / mmol). Moreover, the higher pressures on the pulmonary artery, the greater the concentration of VEGF in serum of patients (r = 0,73). VEGF values was higher in patients with echocardiographic signs of diastolic dysfunction than in children with normal cardiohemodynamic indicators. Conclusion: The determination of the concentration of VEGF in patients with asthma reveals early signs of emerging pulmonary hypertension, which determines the timeliness of appointments optimal therapy.